Correspondence should be addressed to:
AstraZeneca Innovation Center China, R&D Information China, Building 7, No.898 Halei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China
AstraZeneca’s Oncology in vivo data integration platform brings multidimensional data from animal model efficacy, pharmacokinetic and pharmacodynamic data to animal model profiling data and public in vivo studies. Using this platform, scientists can cluster model efficacy and model profiling data together, quickly identify responder profiles and correlate molecular characteristics to pharmacological response. Through meta-analysis, scientists can compare pharmacology between single and combination treatments, between different drug scheduling and administration routes.